Trial: 201710148

A Multi-Center, Open-Label, Phase 1/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients with Advanced Solid Tumors

Phase

I

Principal Investigator

Park, Haeseong

Disease Site

Anus; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Donor; Esophagus; Eye and Orbit; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Sarcoma; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder; Uveal Tract Melanoma

Learn more about this study at: clinicaltrials.gov